• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CYP3A5 Gene Record

  • Summary
  • Interactions
  • Claims
  • CYP3A5 1577 Druggable Genome

    Alternate Names:

    1577
    CYTOCHROME P450 FAMILY 3 SUBFAMILY A MEMBER 5
    CYP3A5
    CP35
    CYPIIIA5
    P450PCN3
    PCN3
    605325
    2638
    ENSG00000106258
    OTTHUMG00000156724
    P20815
    CP3A5_HUMAN
    CYTOCHROME P450 3A5
    Cytochrome P450 HLp2
    Cytochrome P450-PCN3
    CYTOCHROME P450 3A5 (EC 1.14.14.1) (CYPIIIA5) (P450-PCN3) (HLP2). [SOURCE:UNIPROT/SWISSPROT;ACC:P20815]
    PA131

    Gene Info:

    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Human Readable Name DRUGGABLE GENOME
    Interpro Short Name Cyt_P450
    Human Readable Name CYTOCHROME P450
    Interpro Acc IPR001128
    Interpro Type Family
    Interpro Name Cytochrome P450
    Target Class Enzymes
    Target Subclass EC:1.14.14.1
    Gene Biotype PROTEIN_CODING
    (8 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    CYTOCHROME P450
    ENZYME

    Publications:

    Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Bailey KM et al., 2010, Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study., Circ Cardiovasc Genet
    Ueshima S et al., 2018, Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation., Br J Clin Pharmacol
    Ueshima S et al., 2017, Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation., Pharmacogenet Genomics
    Kim KA et al., 2006, Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects., Clin Pharmacol Ther
    Li et al., 2007, Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes., Clin. Cancer Res.
    Chan EC et al., 2012, Interaction of lapatinib with cytochrome P450 3A5., Drug Metab Dispos
    Barbara JE et al., 2013, Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate., Drug Metab Dispos
    Kim KA et al., 2014, Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers., Pharmacogenet Genomics
    Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics
    Luzum JA et al., 2015, Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations., J Cardiovasc Pharmacol
    Tsamandouras N et al., 2014, Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach., Clin Pharmacol Ther
    Hu M et al., 2013, Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia., Pharmacogenomics
    Zuccaro P et al., 2007, Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin., Pharmacol Res
    Kim KA et al., 2007, Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects., J Clin Pharmacol
    Fiegenbaum et al., 2005, The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment., Clin. Pharmacol. Ther.
    Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics
    Pu J et al., 2019, Correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer., Eur Rev Med Pharmacol Sci
    Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.
    Cabaleiro T et al., 2013, Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects., Hum Psychopharmacol
    Ashirmetov et al., [The role of the parasympathetic nervous system in the regulation of microsomal monooxygenase activity in the liver of rats]., Fiziol Zh
    Tu et al., 1983, Induction of a high affinity nitrosamine demethylase in rat liver microsomes by acetone and isopropanol., Chem. Biol. Interact.
    Stamer UM et al., 2011, CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care., Anesth Analg
    Yin OQ et al., 2010, CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition., J Clin Pharmacol
    Haas DM et al., 2013, Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic., Am J Perinatol
    Abell LM et al., 2011, Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro., J Pharmacol Exp Ther
    Gozalo C et al., 2011, Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial., Basic Clin Pharmacol Toxicol
    Ciccacci C et al., 2010, Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique., Pharmacogenomics
    Mahungu T et al., 2009, Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population., HIV Med
    Hu L et al., 2016, Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients., J Clin Pharmacol
    Leskelä S et al., 2011, Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity., Pharmacogenomics J
    García-Martín et al., 2006, Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8., Pharmacogenomics
    Willrich MA et al., 2008, CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia., Clin Chim Acta
    Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
    Wilke RA et al., 2005, Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage., Pharmacogenet Genomics
    Wang P et al., 2015, Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy., Epilepsy Res
    Zhu X et al., 2014, Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy., Pharmacogenomics
    Saruwatari J et al., 2014, Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction., Pharmacogenet Genomics
    Puranik YG et al., 2013, Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy., Pharmacogenomics
    Thorn CF et al., 2011, PharmGKB summary: carbamazepine pathway., Pharmacogenet Genomics
    Hennessy EJ et al., 2015, Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity., J Med Chem
    Bustos ML et al., 2016, Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting., Pharmacotherapy
    Zhou X et al., 2018, Effect of breviscapine on CYP3A metabolic activity in healthy volunteers., Eur J Clin Pharmacol
    Vyhlidal CA et al., 2015, Variability in Expression of CYP3A5 in Human Fetal Liver., Drug Metab Dispos
    Seng KY et al., 2014, CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients., J Clin Pharmacol
    Elens L et al., 2013, CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin., Pharmacogenomics
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
    Granfors et al., 2006, Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro., Basic Clin. Pharmacol. Toxicol.
    Zubiaur P et al., 2020, Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran., Adv Ther
    Sukasem C et al., 2014, Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults., Drug Metab Pharmacokinet
    Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
    Chen J et al., 2010, CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients., Ther Drug Monit
    Haas DW et al., 2005, Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study., J Infect Dis
    Haas DW et al., 2004, Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study., AIDS
    Ehmann F et al., 2014, European Medicines Agency initiatives and perspectives on pharmacogenomics., Br J Clin Pharmacol
    Zhao Y et al., 2009, Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort., Eur J Clin Pharmacol
    Rodríguez-Jiménez C et al., 2017, Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant., Drug Metab Pers Ther
    Li Y et al., 2015, CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients., Springerplus
    Emoto C et al., 2015, The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model., Br J Clin Pharmacol
    Woillard JB et al., 2013, Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients., Clin Chem
    Sam WJ et al., 2011, Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients., Transplantation
    Miao LY et al., 2008, Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients., Biopharm Drug Dispos
    Le Meur Y et al., 2006, CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients., Clin Pharmacol Ther
    Anglicheau D et al., 2005, Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy., Am J Transplant
    Saiz-Rodríguez M et al., 2019, Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects., Basic Clin Pharmacol Toxicol
    Ishida T et al., 2016, Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain., Drug Metab Pharmacokinet
    Tanaka N et al., 2014, Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period., Ther Drug Monit
    Takashina Y et al., 2012, Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system., Drug Metab Pharmacokinet
    Lesche D et al., 2015, Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation., Clin Transplant
    Schoeppler KE et al., 2014, The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients., Clin Transplant
    Naito T et al., 2011, CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone., J Clin Pharmacol
    Shon JH et al., 2011, The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype., Pharmacogenet Genomics
    Kim HR et al., 2013, Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients., Cancer Chemother Pharmacol
    Garcia-Donas J et al., 2011, Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study., Lancet Oncol
    Adeagbo BA et al., 2016, Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia., J Clin Pharm Ther
  • VARDENAFIL   CYP3A5

    Interaction Score: 0.6

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21934637


    Sources:
    PharmGKB

  • APIXABAN   CYP3A5

    Interaction Score: 0.6

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29457840 28678049


    Sources:
    PharmGKB

  • PROPOXYPHENE   CYP3A5

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20133509 18695978


    Sources:
    PharmGKB

  • TADALAFIL   CYP3A5

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • CLINDAMYCIN   CYP3A5

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • ISOPROPYL ALCOHOL   CYP3A5

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6409434


    Sources:
    NCI

  • CHLORPHENIRAMINE   CYP3A5

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • SALMETEROL   CYP3A5

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • AMPRENAVIR   CYP3A5

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16433896


    Sources:
    NCI

  • MELOXICAM   CYP3A5

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • MEPERIDINE   CYP3A5

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • HYDROMORPHONE   CYP3A5

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • CYCLOBENZAPRINE   CYP3A5

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • HYDROCODONE   CYP3A5

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • SIBUTRAMINE   CYP3A5

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • PRASUGREL   CYP3A5

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21828263


    Sources:
    PharmGKB FDA

  • OXYCODONE   CYP3A5

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21209234 18695978


    Sources:
    PharmGKB

  • TAMSULOSIN   CYP3A5

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • SILDENAFIL   CYP3A5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • DONEPEZIL   CYP3A5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • EFAVIRENZ   CYP3A5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24477223 20860463 20625352 16267764 15622315


    Sources:
    PharmGKB

  • PANTOPRAZOLE   CYP3A5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • BUSPIRONE   CYP3A5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • SUFENTANIL   CYP3A5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31773688


    Sources:
    PharmGKB

  • LUMEFANTRINE   CYP3A5

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • HYDROXYZINE   CYP3A5

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • FENTANYL   CYP3A5

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30281924 27236640 24365989 22277678 18695978


    Sources:
    PharmGKB

  • LOSARTAN   CYP3A5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • DABIGATRAN   CYP3A5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    32564268


    Sources:
    PharmGKB

  • ONDANSETRON   CYP3A5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21596874


    Sources:
    PharmGKB

  • ESOMEPRAZOLE   CYP3A5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • RIFAMPIN   CYP3A5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26291341 18695978


    Sources:
    DTC PharmGKB

  • COBICISTAT   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cytochrome P450 3A inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CLOPIDOGREL   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21828263 20938371


    Sources:
    DTC PharmGKB

  • DOLUTEGRAVIR   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ARTEMETHER   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TERAZOSIN   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • MODAFINIL   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • BUPRENORPHINE   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • CARBAMAZEPINE   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12673034 26421491 25495409 24384557 23252947 21738081 18695978


    Sources:
    NCI PharmGKB

  • SIMVASTATIN   CYP3A5

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26164721 24598718 23252946 18695978 17289397 17192506 16321621 15284534


    Sources:
    NCI PharmGKB

  • ISOTRETINOIN   CYP3A5

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • ATROPINE   CYP3A5

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2128054


    Sources:
    NCI

  • NEVIRAPINE   CYP3A5

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21824325 20017669 19228205


    Sources:
    PharmGKB

  • AXITINIB   CYP3A5

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24433361


    Sources:
    PharmGKB

  • AMLODIPINE   CYP3A5

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17178265


    Sources:
    PharmGKB

  • SIROLIMUS   CYP3A5

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28245187 26543771 26256674 23974086 22094953 17941052 16815317 15707415


    Sources:
    PharmGKB

  • GRANISETRON   CYP3A5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27809336


    Sources:
    PharmGKB

  • TRAZODONE   CYP3A5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • CLARITHROMYCIN   CYP3A5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • ROSUVASTATIN   CYP3A5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20207952


    Sources:
    PharmGKB

  • BOCEPREVIR   CYP3A5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • MEDROXYPROGESTERONE ACETATE   CYP3A5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • TESMILIFENE   CYP3A5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name tesmilifene
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • MIDAZOLAM   CYP3A5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28986606 25979262 24214410 23327575


    Sources:
    PharmGKB

  • VENLAFAXINE   CYP3A5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • NIMODIPINE   CYP3A5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19205682


    Sources:
    PharmGKB

  • PIOGLITAZONE   CYP3A5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • LORATADINE   CYP3A5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • ATORVASTATIN   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18727922 18695978 17289397 16103896 15900215 15284534


    Sources:
    PharmGKB

  • LOPINAVIR   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ZOLPIDEM   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • MONTELUKAST   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • ESZOPICLONE   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • QUETIAPINE   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24240480 18695978


    Sources:
    PharmGKB

  • LAPATINIB   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22511346 23404373


    Sources:
    DTC

  • ZIPRASIDONE   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • TRAMADOL   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • ERYTHROMYCIN   CYP3A5

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • MIRTAZAPINE   CYP3A5

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • SERTRALINE   CYP3A5

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • AMIODARONE   CYP3A5

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • CILOSTAZOL   CYP3A5

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PREDNISOLONE   CYP3A5

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12673034


    Sources:
    NCI

  • SUNITINIB   CYP3A5

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24013576 22015057


    Sources:
    PharmGKB

  • LANSOPRAZOLE   CYP3A5

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • EVEROLIMUS   CYP3A5

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26458301 24628014


    Sources:
    PharmGKB

  • FLUOXETINE   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • LOVASTATIN   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978 15284534


    Sources:
    PharmGKB

  • FENOFIBRATE   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • TRETINOIN   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • ALPRAZOLAM   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • DIAZEPAM   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • OMEPRAZOLE   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • CITALOPRAM   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • WARFARIN   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • RITONAVIR   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PACLITAXEL   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26179145 20212519 16753005


    Sources:
    NCI PharmGKB

  • PHENYTOIN   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12673034


    Sources:
    NCI

  • FLUVASTATIN   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • HALOPERIDOL   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 18695978


    Sources:
    PharmGKB

  • PAROXETINE   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NIFEDIPINE   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22875663


    Sources:
    PharmGKB

  • TRIAZOLAM   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CYCLOSPORINE   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12673034


    Sources:
    NCI

  • IMATINIB   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27426203


    Sources:
    PharmGKB

  • CELECOXIB   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • PROGESTERONE   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • OLANZAPINE   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23559402


    Sources:
    PharmGKB

  • GEFITINIB   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17575239


    Sources:
    NCI

  • DOCETAXEL   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • CARBOPLATIN   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26179145


    Sources:
    PharmGKB

  • VINCRISTINE   CYP3A5

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000106258

    • Version: 101_38

    Alternate Names:
    CYP3A5 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000106258

    • Version: 26-July-2011

    Alternate Names:
    CYP3A5 Display Id
    CYTOCHROME P450 3A5 (EC 1.14.14.1) (CYPIIIA5) (P450-PCN3) (HLP2). [SOURCE:UNIPROT/SWISSPROT;ACC:P20815] Description
    ENSG00000106258 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P20815

    • Version: 11-September-2012

    Alternate Names:
    CYP3A5 Uniprot Gene Name
    ENSG00000106258 Ensembl Gene Id
    CP3A5_HUMAN Uniprot Id

    Gene Info:
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME, CYTOCHROME P450

    Publications:

  • TdgClinicalTrial: P20815

    • Version: January-2014

    Alternate Names:
    CYP3A5 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:1.14.14.1

    Publications:

  • PharmGKB: CYP3A5

    • Version: 18-August-2020

    Alternate Names:
    PA131 PharmGKB ID

    Gene Info:

    Publications:
    Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Bailey KM et al., 2010, Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study., Circ Cardiovasc Genet

  • NCI: CYP3A5

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.
    Rühl et al., 2004, Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor., Eur J Nutr
    Tu et al., 1983, Induction of a high affinity nitrosamine demethylase in rat liver microsomes by acetone and isopropanol., Chem. Biol. Interact.

  • DTC: CYP3A5

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Hennessy EJ et al., 2015, Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity., J Med Chem
    Barbara JE et al., 2013, Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate., Drug Metab Dispos
    Chan EC et al., 2012, Interaction of lapatinib with cytochrome P450 3A5., Drug Metab Dispos

  • ChemblInteractions: CYP3A5

    • Version: chembl_23

    Alternate Names:
    CYP3A5 GENE_SYMBOL
    Cytochrome P450 3A5 UNIPROT
    CYPIIIA5 UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000106258

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000106258 Gene Symbol
    CYP3A5 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Tempus: CYP3A5

    • Version: 11-November-2018

    Alternate Names:
    CYP3A5 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Pharos: CYP3A5

    • Version: 01-February-2022

    Alternate Names:
    Cytochrome P450 3A5 Gene Name
    P20815 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • FDA: CYP3A5

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21